Annual EBITDA
-$392.10 M
-$177.81 M-82.98%
December 31, 2023
Summary
- As of February 26, 2025, PCVX annual EBITDA is -$392.10 million, with the most recent change of -$177.81 million (-82.98%) on December 31, 2023.
- During the last 3 years, PCVX annual EBITDA has fallen by -$304.29 million (-346.55%).
- PCVX annual EBITDA is now -1281.93% below its all-time high of -$28.37 million, reached on December 31, 2018.
Performance
PCVX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$135.14 M
+$13.97 M+9.37%
September 30, 2024
Summary
- As of February 26, 2025, PCVX quarterly EBITDA is -$135.14 million, with the most recent change of +$13.97 million (+9.37%) on September 30, 2024.
- Over the past year, PCVX quarterly EBITDA has stayed the same.
- PCVX quarterly EBITDA is now -1205.46% below its all-time high of -$10.35 million, reached on June 30, 2019.
Performance
PCVX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$528.22 M
-$26.23 M-5.23%
September 30, 2024
Summary
- As of February 26, 2025, PCVX TTM EBITDA is -$528.22 million, with the most recent change of -$26.23 million (-5.23%) on September 30, 2024.
- Over the past year, PCVX TTM EBITDA has stayed the same.
- PCVX TTM EBITDA is now -3852.54% below its all-time high of -$13.36 million, reached on March 31, 2019.
Performance
PCVX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
PCVX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -83.0% | 0.0% | 0.0% |
| 3 y3 years | -346.6% | -424.6% | -476.8% |
| 5 y5 years | -1281.9% | -1128.1% | -978.0% |
PCVX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -305.8% | at low | -394.0% | +9.4% | -436.1% | at low |
| 5 y | 5-year | -700.2% | at low | -846.2% | +9.4% | -978.0% | at low |
| alltime | all time | -1281.9% | at low | -1205.5% | +9.4% | -3852.5% | at low |
Vaxcyte EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$135.14 M(-9.4%) | -$528.22 M(+5.2%) |
| Jun 2024 | - | -$149.11 M(+34.0%) | -$501.98 M(+15.4%) |
| Mar 2024 | - | -$111.25 M(-16.2%) | -$435.15 M(+11.0%) |
| Dec 2023 | -$392.10 M(+83.0%) | -$132.71 M(+21.9%) | -$392.10 M(+17.0%) |
| Sep 2023 | - | -$108.91 M(+32.4%) | -$335.13 M(+18.9%) |
| Jun 2023 | - | -$82.28 M(+20.7%) | -$281.79 M(+14.6%) |
| Mar 2023 | - | -$68.20 M(-10.0%) | -$245.87 M(+14.7%) |
| Dec 2022 | -$214.29 M(+121.8%) | -$75.75 M(+36.3%) | -$214.36 M(+29.2%) |
| Sep 2022 | - | -$55.56 M(+19.9%) | -$165.97 M(+21.9%) |
| Jun 2022 | - | -$46.36 M(+26.3%) | -$136.16 M(+20.9%) |
| Mar 2022 | - | -$36.69 M(+34.1%) | -$112.61 M(+14.3%) |
| Dec 2021 | -$96.61 M | -$27.36 M(+6.2%) | -$98.54 M(+7.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$25.76 M(+13.0%) | -$91.58 M(+5.9%) |
| Jun 2021 | - | -$22.80 M(+0.8%) | -$86.51 M(+3.4%) |
| Mar 2021 | - | -$22.62 M(+10.8%) | -$83.67 M(-4.7%) |
| Dec 2020 | -$87.81 M(+79.2%) | -$20.41 M(-1.3%) | -$87.81 M(+7.5%) |
| Sep 2020 | - | -$20.68 M(+3.6%) | -$81.68 M(+13.4%) |
| Jun 2020 | - | -$19.96 M(-25.4%) | -$72.00 M(+15.4%) |
| Mar 2020 | - | -$26.75 M(+87.3%) | -$62.39 M(+27.3%) |
| Dec 2019 | -$49.00 M(+72.7%) | -$14.28 M(+29.8%) | -$49.00 M(+41.1%) |
| Sep 2019 | - | -$11.00 M(+6.3%) | -$34.72 M(+46.4%) |
| Jun 2019 | - | -$10.35 M(-22.5%) | -$23.72 M(+77.5%) |
| Mar 2019 | - | -$13.36 M | -$13.36 M |
| Dec 2018 | -$28.37 M | - | - |
FAQ
- What is Vaxcyte annual EBITDA?
- What is the all time high annual EBITDA for Vaxcyte?
- What is Vaxcyte annual EBITDA year-on-year change?
- What is Vaxcyte quarterly EBITDA?
- What is the all time high quarterly EBITDA for Vaxcyte?
- What is Vaxcyte quarterly EBITDA year-on-year change?
- What is Vaxcyte TTM EBITDA?
- What is the all time high TTM EBITDA for Vaxcyte?
- What is Vaxcyte TTM EBITDA year-on-year change?
What is Vaxcyte annual EBITDA?
The current annual EBITDA of PCVX is -$392.10 M
What is the all time high annual EBITDA for Vaxcyte?
Vaxcyte all-time high annual EBITDA is -$28.37 M
What is Vaxcyte annual EBITDA year-on-year change?
Over the past year, PCVX annual EBITDA has changed by -$177.81 M (-82.98%)
What is Vaxcyte quarterly EBITDA?
The current quarterly EBITDA of PCVX is -$135.14 M
What is the all time high quarterly EBITDA for Vaxcyte?
Vaxcyte all-time high quarterly EBITDA is -$10.35 M
What is Vaxcyte quarterly EBITDA year-on-year change?
Over the past year, PCVX quarterly EBITDA has changed by $0.00 (0.00%)
What is Vaxcyte TTM EBITDA?
The current TTM EBITDA of PCVX is -$528.22 M
What is the all time high TTM EBITDA for Vaxcyte?
Vaxcyte all-time high TTM EBITDA is -$13.36 M
What is Vaxcyte TTM EBITDA year-on-year change?
Over the past year, PCVX TTM EBITDA has changed by $0.00 (0.00%)